Клиническое наблюдение сочетания диффузного альвеолярно-септального варианта поражения легких и амилоидной кардиомиопатии при системном AL-амилоидозе в пожилом возрасте

1. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-13. doi: 10.1080/13506129.2016.1257986
2. Козловская Л.В., Рамеев В.В. Амилоидоз. В кн.: Мухин Н.А., редактор. Нефрология. Национальное руководство. М.: ГЭОТАР-Медиа, 2009. С. 272-87 [Kozlovskaya LV, Rameev VV. Amyloidosis. In: Mukhin NA, editor. Nefrologiya. Natsional’noe rukovodstvo [Nephrology. National guidelance]. Moscow: GEOTAR-Media, 2009. P. 272-87 (In Russ.)].
3. Козловская Л.В., Рамеев В.В. Диагностика и лечение АА- и AL-амилоидоза: Клинические рекомендации. М., 2014. [Kozlovskaya LV, Rameev VV. Diagnostika i lechenie AA- i AL-amiloidza: Klinicheskie rekomendatsii [Diagnosis and treatment of AA and AL amyloidosis: Cli­nical guidelines]. Moscow, 2014 (In Russ.)].
4. Рамеев В.В., Козловская Л.В. Амилоидоз: современные методы диагностики и лечения. Эффективная фармакотерапия. Урология и Нефрология. 2012; Спецвыпуск «Актуальные вопросы нефрологии»: 6-15 [Rameev VV, Kozlovskaya LV. Amyloidosis: modern methods of diagnosis and treatment. Effektivnaya Farmakoterapiya. Urologiya i Nefrologiya. 2012; Special issue “Aktual'nye voprosy nefrologii”: 6-15 (In Russ.)].
5. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004;255:159-78. doi: 10.1046/j.1365-2796.2003.01262.x
6. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924-33. doi: 10.1200/jco.2010.32.2271
7. Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis. 2016;2:10-9. doi: 0.1159/000444206
8. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SDJ, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD. Systemic Amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525-32. doi: 10.1111/bjh.12286
9. Fikrle M, Paleček T, Kuchynka P, Němeček E, Bauerová L, Straub J, Ryšavá R. Cardiac amyloidosis: A comprehensive review. Cor et Vasa. 2013;55(1):e60-e75. doi: 10.1016/j.crvasa.2012.11.018
10. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(12):1323-41. doi: 10.1016/j.jacc.2016.06.053
11. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-33. doi: 10.1200/jco.2010.32.2271
12. Рамеев В.В., Козловская Л.В., Жданова Е.А. и др. Кардиоренальные взаимосвязи при системном амилоидозе. Терапевтический архив. 2013;6:51-9 [Rameev VV, Kozlovskaya LV, Zhdanova EA, et al. Cardiorenal interrelations with systemic amyloidosis. Ter Arkh. 2013;6:51-9 (In Russ.)].
13. Жданова Е.А., Рамеев В.В., Моисеев С.В., Козловская Л.В., Сафарова А.Ф. Амилоидоз сердца. Клиническая фармакология и терапия. 2011;20(5):44-50 [Zhdanova EA, Rameev VV, Moiseev SV, Kozlovskaya LV, Safarova AF. Amyloidosis of the heart. Klinicheskaya Farmakologiya i Terapiya. 2011;20(5):44-50 (In Russ.)].
14. Berk JL, O'regan A, Skinner M. Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med. 2002;23(02):155-66. doi: 10.1055/s-2002-25304
15. Khoor A, Colby TV. Amyloidosis of the Lung. Arch Pathol Lab Med. 2017;141(2):247-54. doi: 10.5858/arpa.2016-0102-ra
16. Pitz MW, Gibson IW, Johnston JB. Isolated pulmonary amyloidosis: Case report and review of the literature. Am J Hematol. 2006;81(3):212-3. doi: 10.1002/ajh.20518
17. Road JD, Jacques J, Sparling JR. Diffuse alveolar septal amyloidosis presenting with recurrent hemoptysis and medial dissection of pulmonary arteries. Am Rev Resp Dis. 1985;132:1368-70.
18. Ferris HW. Amyloidosis of lungs and heart. Am J Path. 1936;12:701-18.
19. Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis: Updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051
20. Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol. 2013;167(5):2156-61. doi: 10.1016/j.ijcard.2012.05.097

________________________________________________

1. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-13. doi: 10.1080/13506129.2016.1257986
2. [Kozlovskaya LV, Rameev VV. Amyloidosis. In: Mukhin NA, editor. Nefrologiya. Natsional’noe rukovodstvo [Nephrology. National guidelance]. Moscow: GEOTAR-Media, 2009. P. 272-87 (In Russ.)].
3. [Diagnosis and treatment of AA and AL amyloidosis: Cli­nical guidelines]. Moscow, 2014 (In Russ.)].
4. [Rameev VV, Kozlovskaya LV. Amyloidosis: modern methods of diagnosis and treatment. Effektivnaya Farmakoterapiya. Urologiya i Nefrologiya. 2012; Special issue “Aktual'nye voprosy nefrologii”: 6-15 (In Russ.)].
5. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004;255:159-78. doi: 10.1046/j.1365-2796.2003.01262.x
6. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924-33. doi: 10.1200/jco.2010.32.2271
7. Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis. 2016;2:10-9. doi: 0.1159/000444206
8. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SDJ, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD. Systemic Amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525-32. doi: 10.1111/bjh.12286
9. Fikrle M, Paleček T, Kuchynka P, Němeček E, Bauerová L, Straub J, Ryšavá R. Cardiac amyloidosis: A comprehensive review. Cor et Vasa. 2013;55(1):e60-e75. doi: 10.1016/j.crvasa.2012.11.018
10. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(12):1323-41. doi: 10.1016/j.jacc.2016.06.053
11. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-33. doi: 10.1200/jco.2010.32.2271
12. [Rameev VV, Kozlovskaya LV, Zhdanova EA, et al. Cardiorenal interrelations with systemic amyloidosis. Ter Arkh. 2013;6:51-9 (In Russ.)].
13. [Zhdanova EA, Rameev VV, Moiseev SV, Kozlovskaya LV, Safarova AF. Amyloidosis of the heart. Klinicheskaya Farmakologiya i Terapiya. 2011;20(5):44-50 (In Russ.)].
14. Berk JL, O'regan A, Skinner M. Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med. 2002;23(02):155-66. doi: 10.1055/s-2002-25304
15. Khoor A, Colby TV. Amyloidosis of the Lung. Arch Pathol Lab Med. 2017;141(2):247-54. doi: 10.5858/arpa.2016-0102-ra
16. Pitz MW, Gibson IW, Johnston JB. Isolated pulmonary amyloidosis: Case report and review of the literature. Am J Hematol. 2006;81(3):212-3. doi: 10.1002/ajh.20518
17. Road JD, Jacques J, Sparling JR. Diffuse alveolar septal amyloidosis presenting with recurrent hemoptysis and medial dissection of pulmonary arteries. Am Rev Resp Dis. 1985;132:1368-70.
18. Ferris HW. Amyloidosis of lungs and heart. Am J Path. 1936;12:701-18.
19. Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis: Updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051
20. Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol. 2013;167(5):2156-61. doi: 10.1016/j.ijcard.2012.05.097

А.Ю. Третьяков 1, С.П. Захарченко1 , В.А. Третьякова 2, О.В. Ермилов 1, С.А. Шеховцов 3, Р.Р. Хабибулин 3, К.С. Алейникова 1, В.С. Дан 1, Н.А. Лещева 4

1 ФГАОУ ВО «Белгородский государственный национальный исследовательский университет», Белгород, Россия;
2 ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия;
3 ОГБУЗ «Белгородская областная клиническая больница Святителя Иоасафа», Белгород, Россия;
4 ОГКУЗ «Противотуберкулезный диспансер» Белгород, Россия

________________________________________________

A.Yu. Tret'yakov 1, S.P. Zakharchenko 1, V.A. Tret'yakova 2, O.V. Ermilov 1, S.A. Shekhovtsov 3, R.R. Khabibulin 2, K.S. Aleinikova 1, V.S. Dan 1, N.A. Leshcheva 4

1 Belgorod National Research University, Belgorod, Russia;
2 People’s Friendship University of Russia (RUDN University), Moscow, Russia;
3 Belgorod Regional Clinical Hospital of St. Joasaph, Belgorod, Russia;
4 Tuberculosis dispensary, Belgorod, Russia